Project Details
| Short title | V940-004 |
|---|---|
| Acronym | V940-004 |
| Status | Active |
| Effective start/end date | 8/03/24 → 27/09/28 |
CTU: A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants with Renal Cell Carcinoma
- Gurney, Howard (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
Project: Research